Literature DB >> 19889300

[Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma].

F M Almazán-Fernández1, S Serrano-Ortega, J J Moreno-Villalonga.   

Abstract

INTRODUCTION: Every year, health expenditure in Spain increases and, with it, the resources dedicated to cancer treatment. Cutaneous melanoma is the skin cancer with the highest morbidity and mortality.
OBJECTIVES: We performed a descriptive study of the costs, based on a theoretical model, to determine the healthcare expenditure for patients with cutaneous melanoma; the objective was to define the overall costs (direct and indirect) of the diagnostic and treatment process of cutaneous melanoma, divided into different stages or diagnostic-therapeutic steps, and the possible variations in these costs.
MATERIAL AND METHODS: For this purpose, we used the Andalusian analytical accountancy program of hospitals and districts (COAN-hyd) and the total costs module of the COAN for 2007, applied to the protocol we use in the melanoma unit of our hospital.
CONCLUSIONS: The most important conclusions were that the greatest health care expenditure was observed inpatients with more advanced melanomas, with a poor prognosis. Management of the diagnostic-therapeutic process by dermatologists, the appropriate use of complementary tests, and operations performed by dermatologists reduce costs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889300

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  6 in total

1.  Somatic Mutations in TP53 Gene in Colombian Patients With Non-melanoma Skin Cancer.

Authors:  Luz Dary Gutiérrez-Castañeda; María Irene Cerezo-Cortés; John Nova
Journal:  Cancer Diagn Progn       Date:  2022-01-03

Review 2.  Melanoma treatment costs: a systematic review of the literature, 1990-2011.

Authors:  Gery P Guy; Donatus U Ekwueme; Florence K Tangka; Lisa C Richardson
Journal:  Am J Prev Med       Date:  2012-11       Impact factor: 5.043

3.  Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

Authors:  Grant A McArthur; Peter Mohr; Paolo Antonio Ascierto; Ana Arance; Ana Banos Hernaez; Peter Kaskel; Michael Weichenthal; Reshma Shinde; Kendall Stevinson
Journal:  Oncologist       Date:  2017-05-19

4.  Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Authors:  Ahmad Tarhini; Sameer R Ghate; Raluca Ionescu-Ittu; Ameur M Manceur; Briana Ndife; Philippe Jacques; François Laliberté; Antonio Nakasato; Rebecca Burne; Mei Sheng Duh
Journal:  Melanoma Res       Date:  2018-12       Impact factor: 3.599

5.  The cost of unresectable stage III or stage IV melanoma in Italy.

Authors:  Michele Maio; Paolo Ascierto; Alessandro Testori; Ruggero Ridolfi; Emilio Bajetta; Paola Queirolo; Michele Guida; Antonella Romanini; Vanna Chiarion-Sileni; Jacopo Pigozzo; Anna Maria Di Giacomo; Mario Calandriello; Guido Didoni; Marck van Baardewijk; Cyril Konto; Carlo Lucioni
Journal:  J Exp Clin Cancer Res       Date:  2012-11-01

6.  Cutaneous melanoma follow-up: appropriateness of requests for ultrasound tests--the S.Gallicano National Referral Centre Experience.

Authors:  Francesco M Solivetti; Fulvia Elia; Antonino Guerrisi; Flora Desiderio; Maria Santaguida; Isabella Sperduti; Claudia Cavallotti; Aldo Di Carlo
Journal:  J Exp Clin Cancer Res       Date:  2013-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.